(Q33331583)

25 July 2017

title

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer (English)

1 reference

25 July 2017

1 reference

K D Miller

1

1 reference

25 July 2017

J Picus

2

1 reference

25 July 2017

C Blanke

3

1 reference

25 July 2017

W John

4

1 reference

25 July 2017

J Clark

5

1 reference

25 July 2017

L N Shulman

6

1 reference

25 July 2017

D Thornton

7

1 reference

25 July 2017

E Rowinsky

8

1 reference

25 July 2017

P J Loehrer

9

1 reference

25 July 2017

publication date

1 January 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

11

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

101-103

1 reference

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Clinical studies with MTA.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008305205159

7 January 2021

Identifiers

DOI

10.1023/A:1008305205159

1 reference

25 July 2017

1 reference